Author | Louis S. Goodman and Alfred Gilman |
---|---|
Publication date | 1941 |
Goodman & Gilman's The Pharmacological Basis of Therapeutics, commonly referred to as the Blue Bible or Goodman & Gilman, is a textbook of pharmacology originally authored by Louis S. Goodman and Alfred Gilman. First published in 1941, the book is in its 14th edition (as of 2022), and has the reputation of being the "bible of pharmacology". The readership of this book include physicians of all therapeutic and surgical specialties, clinical pharmacologists, clinical research professionals and pharmacists.
While teaching jointly in the Yale School of Medicine's Department of Pharmacology, Goodman and Gilman began developing a course textbook that emphasized relationships between pharmacodynamics and pharmacotherapy, introduced recent pharmacological advances like sulfa drugs, and discussed the history of drug development. [1] [2] Yale physiologist John Farquhar Fulton encouraged them to publish the work for a broader audience and introduced them to a publisher at the Macmillan Publishing Company. [1] Their new text was first published in 1941 under the title The Pharmacological Basis of Therapeutics: A Textbook of Pharmacology, Toxicology and Therapeutics for Physicians and Medical Student. [1] Because the volume was twice as long as a typical textbook, Macmillan printed few copies, but demand for a readable, up-to-date pharmacological text proved high, and several printings followed. [2]
Although rapid pharmacological innovations were made in the years immediately following—including the introduction of chemotherapy, steroids, antibiotics, and antihistamines—a second edition could not be completed until 1955 because of the authors' service in World War II. [2] [1] Thereafter, the text was revised every five years in collaboration with a large number of specialist coauthors. [1]
Gilman and Goodman remained the book's lead editors for the first five editions; Gilman remained an editor through the sixth edition, and Goodman through the seventh, which was published shortly after Gilman's death in 1984. Alfred Goodman Gilman, the son of Alfred Gilman and winner of the 1994 Nobel Prize in Medicine and Physiology, joined as senior editor for the book's sixth, seventh, and eighth editions, and a contributing editor to the ninth and tenth. [3] Goodman died in 2000, and Goodman Gilman in December 2015.
The first five editions were published under the title The Pharmacological Basis of Therapeutics: A Textbook of Pharmacology, Toxicology, and Therapeutics for Physicians and Medical Students.
{{cite book}}
: Missing or empty |title=
(help) 1387 pp.Editions 6 onwards were published under the title Goodman & Gilman's The Pharmacological Basis of Therapeutics.
There have been many published book reviews of this widely used textbook. The first edition reviewer was highly enthusiastic and said that he was “delirious in his appraisal of the book”, that it was an “amazing work”, and “the product of enormous industry and keen insight”. [4] A reviewer of the eighteen-hundred page second-edition described it as encyclopedic, indispensable, and as an excellent resource for students. [5] The fourth edition reviewer noted that “all other related books seem to pale by comparison”. [6] The 6th edition published in 1980 was praised for the extensive bibliography, but also noted that, although “this book is recommended to all those who prescribe drugs”, it had become “too large to be used by medical students as a routine textbook”. [7] The ninth edition was designated as the "blue bible of pharmacology" and as the gold standard. [8] The 12th edition was criticized for only one-ninth of authors being female. [9] However, this had increased to one-fifth of the authors being female in the thirteen-edition. A policy of the editors has been to not disclose the potential conflicts of interest by the authors. The 12th edition authors were the recipients of over one-hundred and thirty patents. [10] The thirteenth edition authors received three-million dollars from pharmaceutical companies which was undisclosed. Unlike earlier editions which were praised for being up to date, [4] an analysis of the 13th edition found that the citations were older than those of other pharmacology textbooks. [9] A team of the reviewers for the 2018 edition were more measured than those of earlier editions. [9]
Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. It is regarded as a second-line option compared to metformin, due to metformin's well-established safety and efficacy. Use of glimepiride is recommended in conjunction with lifestyle modifications such as diet and exercise. It is taken by mouth, reaching a peak effect within three hours and lasting for about a day.
The melanocyte-stimulating hormones, known collectively as MSH, also known as melanotropins or intermedins, are a family of peptide hormones and neuropeptides consisting of α-melanocyte-stimulating hormone (α-MSH), β-melanocyte-stimulating hormone (β-MSH), and γ-melanocyte-stimulating hormone (γ-MSH) that are produced by cells in the pars intermedia of the anterior lobe of the pituitary gland.
An osmotic diuretic is a type of diuretic that inhibits reabsorption of water and sodium (Na). They are pharmacologically inert substances that are given intravenously. They increase the osmolarity of blood and renal filtrate. This fluid eventually becomes urine.
Alfred Goodman Gilman was an American pharmacologist and biochemist. He and Martin Rodbell shared the 1994 Nobel Prize in Physiology or Medicine "for their discovery of G-proteins and the role of these proteins in signal transduction in cells."
The ciliary muscle is an intrinsic muscle of the eye formed as a ring of smooth muscle in the eye's middle layer, the uvea. It controls accommodation for viewing objects at varying distances and regulates the flow of aqueous humor into Schlemm's canal. It also changes the shape of the lens within the eye but not the size of the pupil which is carried out by the sphincter pupillae muscle and dilator pupillae.
Desipramine, sold under the brand name Norpramin among others, is a tricyclic antidepressant (TCA) used in the treatment of depression. It acts as a relatively selective norepinephrine reuptake inhibitor, though it does also have other activities such as weak serotonin reuptake inhibitory, α1-blocking, antihistamine, and anticholinergic effects. The drug is not considered a first-line treatment for depression since the introduction of selective serotonin reuptake inhibitor (SSRI) antidepressants, which have fewer side effects and are safer in overdose.
Mebendazole (MBZ), sold under the brand name Vermox among others, is a medication used to treat a number of parasitic worm infestations. This includes ascariasis, pinworm infection, hookworm infections, guinea worm infections, hydatid disease, and giardia, among others. It is taken by mouth.
Hiram Houston Merritt Jr. was a renowned academic neurologist. Serving as chair of the Neurological Institute of New York and Neurologist-in-Chief at NewYork-Presbyterian Hospital/Columbia University Medical Center in Manhattan's Washington Heights from 1948 to 1967, Merritt played a pivotal role in the training of numerous neurologists, with 35 of his students ascending to department chair positions in universities across the US. He also held the deanship of the Columbia University College of Physicians and Surgeons from 1958 to 1970.
Dobutamine is a medication used in the treatment of cardiogenic shock and severe heart failure. It may also be used in certain types of cardiac stress tests. It is given by IV only, as an injection into a vein or intraosseous as a continuous infusion. The amount of medication needs to be adjusted to the desired effect. Onset of effects is generally seen within 2 minutes. It has a half-life of two minutes. This drug is generally only administered short term, although it may be used for longer periods to relieve symptoms of heart failure in patients awaiting heart transplantation.
Butyrophenone is an organic compound with the formula C6H5C(O)C3H7. It is a colorless liquid.
A nicotinic antagonist is a type of anticholinergic drug that inhibits the action of acetylcholine (ACh) at nicotinic acetylcholine receptors. These compounds are mainly used for peripheral muscle paralysis in surgery, the classical agent of this type being tubocurarine, but some centrally acting compounds such as bupropion, mecamylamine, and 18-methoxycoronaridine block nicotinic acetylcholine receptors in the brain and have been proposed for treating nicotine addiction.
Adrenergic means "working on adrenaline (epinephrine) or noradrenaline (norepinephrine)". When not further qualified, it is usually used in the sense of enhancing or mimicking the effects of epinephrine and norepinephrine in the body.
The respiratory center is located in the medulla oblongata and pons, in the brainstem. The respiratory center is made up of three major respiratory groups of neurons, two in the medulla and one in the pons. In the medulla they are the dorsal respiratory group, and the ventral respiratory group. In the pons, the pontine respiratory group includes two areas known as the pneumotaxic center and the apneustic center.
Senna glycoside, also known as sennoside or senna, is a medication used to treat constipation and empty the large intestine before surgery. The medication is taken by mouth or via the rectum. It typically begins working in around 30 minutes when given by rectum and within twelve hours when given by mouth. It is a weaker laxative than bisacodyl and castor oil.
Alfred Zack Gilman was an American pharmacologist best known for pioneering early chemotherapy techniques using nitrogen mustard with his colleague, Louis S. Goodman. The pair also published the classic textbook The Pharmacological Basis of Therapeutics in 1941, and Gilman served as an editor for its first six editions. Gilman served on the faculties of the Yale School of Medicine, the Columbia College of Physicians and Surgeons, and the Albert Einstein College of Medicine, where he founded the Department of Pharmacology. He was a member of U.S. National Academy of Sciences.
A norepinephrine releasing agent (NRA), also known as an adrenergic releasing agent, is a catecholaminergic type of drug that induces the release of norepinephrine (noradrenaline) and epinephrine (adrenaline) from the pre-synaptic neuron into the synapse. This in turn leads to increased extracellular concentrations of norepinephrine and epinephrine therefore an increase in adrenergic neurotransmission.
In toxicology, the median toxic dose (TD50) of a drug or toxin is the dose at which toxicity occurs in 50% of cases. The type of toxicity should be specified for this value to have meaning for practical purposes. The median toxic dose encompasses the category of toxicity that is greater than half maximum effective concentration (ED50) but less than the median lethal dose (LD50). However, for some highly potent toxins (ex. lofentanil, botulinum toxin) the difference between the ED50 and TD50 is so minute that the values assigned to them may be approximated to equal doses. Since toxicity need not be lethal, the TD50 is generally lower than the median lethal dose (LD50), and the latter can be considered an upper bound for the former. However, since the toxicity is above the effective limit, the TD50 is generally greater than the ED50. If the result of a study is a toxic effect that does not result in death, it is classified as this form of toxicity. Toxic effects can be defined differently, sometimes considering the therapeutic effect of a substance to be toxic (such as with chemotherapeutics) which can lead to confusion and contention regarding a substance's TD50. Examples of these toxic endpoints include cancer, blindness, anemia, and birth defects.
Louis Sanford Goodman was an American pharmacologist. He is best known for his collaborations with Alfred Gilman, Sr., with whom he authored the popular textbook The Pharmacological Basis of Therapeutics in 1941 and pioneered the first chemotherapy trials using nitrogen mustard.
Enasidenib, sold under the brand name Idhifa, is an anti-cancer medication used to treat relapsed or refractory acute myeloid leukemia. It is an inhibitor of isocitrate dehydrogenase 2 (IDH2).
Normustine, also known as bis(2-chloroethyl)carbamic acid, is a nitrogen mustard and alkylating antineoplastic agent. It is a metabolite of a number of antineoplastic agents that have been developed for the treatment of tumors, including estramustine phosphate, alestramustine, cytestrol acetate, and ICI-85966 (stilbostat), but only the former of which has actually been marketed.